Source: BioSpace

Meridian Bioscience: Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business; Positive customer feedback for our revogene molecular diagnostics system continues to build; Diagnostics segment new product

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Meridian Bioscience's latest SEC filings

Annual Revenue

Based on data from Meridian Bioscience's latest SEC filings

Employees

John P. Kenny's photo - CEO of Meridian Bioscience

CEO

John P. Kenny

CEO Approval Rating

68/100

Meridian is a life science company that manufactures and distributes diagnostic test kits, rare reagents, specialty biol... Read more